About InFlectis BioScience
InFlectis BioScience is a Healthcare company based in Nantes (France) founded in 2013 by Philippe GuEdat and Pierre Miniou. Small molecules are developed to treat protein misfolding disorders. InFlectis BioScience has raised $8.76 million across 2 funding rounds from investors including GO CAPITAL, Remiges Ventures and Crédit Mutuel Equity. Its chief executive, as recorded, is Philippe GuEdat. InFlectis BioScience offers products and services including Small Molecule Therapeutics. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified.
Company details
InFlectis BioScience was founded in 2013 in Nantes, France, within the biotechnology sector. Small molecule drugs are developed to target cellular mechanisms against misfolded proteins, focusing on neurodegenerative and orphan diseases. Lead programs address Charcot-Marie-Tooth and Retinitis Pigmentosa. IFB-088 modulates the UbiquitinProteasome System via the PP1PPP1R15A interaction, while IFB-008 is advanced for related retinal and neurodegenerative conditions.
- Headquarters Nantes, France
- Founders Philippe GuEdat, Pierre Miniou
- SectorsHealthcare
- Email••••••••
- Website inflectisbioscience.com
- Social LinkedIn
- Total Equity Funding$8.76M (USD)
in 2 rounds
- Latest Funding Round$6.68M (USD), Series A
Jun 2016
- InvestorsGO CAPITAL
& 2 more
Products & Services of InFlectis BioScience
InFlectis BioScience offers a comprehensive portfolio of products and services, including Small Molecule Therapeutics.
Develops brain-penetrant molecules for treating neurological diseases
Funding Insights of InFlectis BioScience
InFlectis BioScience has successfully raised a total of $8.76M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $6.68 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.76M
- Total Rounds 2
- Last Round Series A — $6.68M
- First Round $2.07M
(Jan 2015)
- Investors Count 3
All 2 funding rounds of InFlectis BioScience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $6.68M | Series A | – | Credit Mutuel Equity | |
| Jan 2015 | $2.07M | Seed | – | – |
3 investors in total: 3 institutional.
Investors in InFlectis BioScience
InFlectis BioScience has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include GO CAPITAL, Remiges Ventures and Crédit Mutuel Equity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Remiges Ventures is engaged in biotech venture capital investments. | remigesventures.com | Seattle, United States | ||
Private equity investments are directed toward multiple sectors. | 2003 | gocapital.fr | Rennes, France | |
Growth and acquisition investments are managed by Credit Mutuel Equity. | creditmutuel-equity.eu | Paris, France |
Investor details for InFlectis BioScience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of InFlectis BioScience
2 people are tracked at InFlectis BioScience (2 in leadership).
| Name | Role | Group |
|---|---|---|
Philippe GuEdat | Co-Founder & CEO | Leadership |
Pierre Miniou | Co-Founder | Leadership |
Complete people profiles for InFlectis BioScience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of InFlectis BioScience
3 dated milestones of InFlectis BioScience across 3 years, from founding to its latest funding, stage changes and deals.
- Founded InFlectis BioScience is founded.
- Funding First funding round of $2.1M.
- Funding Latest funding round, Series A, of $6.7M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inflectis Bioscience
Complete news archive for InFlectis BioScience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InFlectis BioScience
InFlectis BioScience was founded in 2013 and raised its 1st funding round 2 years after it was founded.
InFlectis BioScience is headquartered in Nantes, France. It is registered at Nantes, Pays De La Loire, France.
Philippe GuEdat is the CEO of InFlectis BioScience, as recorded in our data. They have also founded this company.
InFlectis BioScience is a funded company, having raised a total of $8.76M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2.07M, raised on Jan 2015.
InFlectis BioScience was founded in 2013 in Nantes, France, within the biotechnology sector. Small molecule drugs are developed to target cellular mechanisms against misfolded proteins, focusing on neurodegenerative and orphan diseases. Lead programs address Charcot-Marie-Tooth and Retinitis Pigmentosa. IFB-088 modulates the UbiquitinProteasome System via the PP1PPP1R15A interaction, while IFB-008 is advanced for related retinal and neurodegenerative conditions.
InFlectis BioScience offers Small Molecule Therapeutics.
InFlectis BioScience has 3 investors. Key investors include GO CAPITAL, Remiges Ventures, and Crédit Mutuel Equity.